Common sense should tell you that an insulin spray like Oral-lyn is more fiction than science. If Oral-lyn was real, Big Pharma would have snatched up the technology a long time ago. Instead, Pfizer lost millions with an insulin bong, and Al Mann, billionaire healthcare entrepreneur and MannKind's founder, is spending hundreds of millions of dollars of his own money to build another inhalable insulin device. For that kind of money, Mann could have bought Generex several times over. He didn't.
Dr. Paul Robertson, a diabetes expert affiliated with the Pacific Northwest Research Institute in Seattle and the past president for medicine and science at the American Diabetes Association (ADA), is a skeptic because absorption of insulin through the lining of the mouth is too erratic and potentially dangerous.
"If a diabetes patient has a sore throat, for instance, the insulin will be absorbed faster than if the patient's throat is normal," he says. "Having a consistent and known rate of insulin absorption is very important because without knowing when to take insulin or how much, the patient runs the risk for hypoglycemia."
David Kliff, a diabetic himself who runs the well-respected Diabetic Investor newsletter, has followed Generex for years and is more succinct in his appraisal. "Generex is full of crap -- always."Oral-lyn is approved as an alternative to insulin injections in Ecuador, India, Lebanon and Algeria, claims Generex, although the company has not yet recognized revenue from the product. Perhaps Oral-lyn will start producing revenue for Generex when it's approved in Syria and Iraq? I'm not making this up, by the way. Generex is trying to get Oral-lyn approved in Iraq and actually touts Oral-lyn's approval in these other countries as proof that it works. A phase III study of Oral-lyn is enrolling patients at centers in the U.S. and Canada, although it looks like most of the patients hail from Eastern Europe. In two years, Generex has only been able to enroll about half of the study's planned 750 patients. Generex does claim to have an agreement with the FDA to allow Oral-lyn to be used by U.S. diabetes patients who can't tolerate insulin injections. Generex has never disclosed how many patients might fit under that definition.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV